Would you recommend patients with newly diagnosed bladder cancer to discontinue SGLT2 inhibitors?

Ask a clinical question

Answers grounded in the literature and physician expertise.

Related Questions

Would you consider utilizing pembrolizumab/enfortumab as a bladder preservation approach in patients with MIBC?

Do the results of IMvigor011 influence you to utilize ctDNA to guide all adjuvant IO in MIBC?

In patients with muscle-invasive bladder cancer, in what clinical scenarios would you consider neoadjuvant cisplatin-based therapy in light of emerging data on enfortumab vedotin plus pembrolizumab?

About Mednet

A community where doctors find answers to medicine's toughest questions.

Verified, credentialed physicians
45,000+ members across 23 specialties
Free CME and MOC credit

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.